Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E46.39 EPS (ttm)2.11 Insider Own0.40% Shs Outstand226.40M Perf Week-14.18%
Market Cap22.12B Forward P/E14.88 EPS next Y6.57 Insider Trans-10.74% Shs Float223.72M Perf Month-23.02%
Income476.80M PEG2.49 EPS next Q1.25 Inst Own96.80% Short Float2.08% Perf Quarter-26.10%
Sales3.25B P/S6.80 EPS this Y162.90% Inst Trans-2.77% Short Ratio1.94 Perf Half Y-17.84%
Book/sh39.54 P/B2.47 EPS next Y23.52% ROA- Target Price159.53 Perf Year-34.06%
Cash/sh6.46 P/C15.13 EPS next 5Y18.65% ROE- 52W Range98.40 - 157.02 Perf YTD-20.15%
Dividend- P/FCF- EPS past 5Y14.00% ROI4.20% 52W High-37.78% Beta1.47
Dividend %- Quick Ratio2.80 Sales past 5Y31.50% Gross Margin91.80% 52W Low-0.71% ATR4.24
Employees3121 Current Ratio3.30 Sales Q/Q24.10% Oper. Margin- RSI (14)21.68 Volatility5.72% 3.39%
OptionableYes Debt/Eq0.34 EPS Q/Q85.20% Profit Margin- Rel Volume2.78 Prev Close98.50
ShortableYes LT Debt/Eq0.32 EarningsApr 27 BMO Payout- Avg Volume2.40M Price97.70
Recom1.90 SMA20-18.55% SMA50-18.26% SMA200-21.91% Volume6,657,798 Change-0.81%
May-25-17Upgrade Morgan Stanley Equal-Weight → Overweight
May-23-17Downgrade JP Morgan Overweight → Neutral
Mar-30-17Initiated UBS Buy $138
Mar-02-17Initiated Instinet Buy $148
Feb-17-17Reiterated RBC Capital Mkts Outperform $187 → $177
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-03-16Initiated Deutsche Bank Buy $164
Oct-28-16Upgrade Goldman Neutral → Buy
Oct-28-16Upgrade FBR & Co. Underperform → Mkt Perform $92 → $130
Oct-28-16Reiterated Wedbush Neutral $132 → $135
Sep-23-16Initiated Wedbush Neutral $132
Sep-16-16Reiterated FBR & Co. Underperform $82 → $92
Sep-15-16Initiated FBR & Co. Underperform $82
Jul-29-16Reiterated Stifel Buy $195 → $182
Jul-29-16Reiterated Barclays Equal Weight $165 → $150
Jul-13-16Reiterated SunTrust Buy $220 → $197
Jul-13-16Initiated RBC Capital Mkts Outperform $188
Jul-11-16Upgrade Credit Suisse Neutral → Outperform $186 → $165
May-29-17 01:00AM  The Good, the Bad and the Ugly; Explaining the Inexplicable: Doug Kass' Views TheStreet.com
May-25-17 10:38AM  2 Key Reasons Morgan Stanley Upgraded Alexion Pharmaceuticals Benzinga
09:52AM  Alexion Pharmaceuticals: Time to Buy? Barrons.com
09:00AM  The Market In 5 Minutes Benzinga
07:36AM  Analysts' Actions -- Kellogg, Kraft Heinz, Altria, PayPal and More TheStreet.com
May-24-17 10:55AM  Alexion Pharmaceuticals: Waiting For the Next Shoe? Barrons.com
10:10AM  Company News for May 24, 2017 Zacks
07:00AM  Trader's Daily Notebook: As Long Weekend Nears, Volume Will Stay Low TheStreet.com
04:00AM  When the Patient Is a Gold Mine: The Trouble With Rare-Disease Drugs Bloomberg
May-23-17 05:50PM  Alexion Shares Drop Amid Executive Changes TheStreet.com -9.34%
05:11PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
05:00PM  Why Herbalife, Alexion Pharmaceuticals, and Brown-Forman Slumped Today Motley Fool
04:24PM  Alexion At Nearly 4-Year Low After Announcing Exits Of 4 Execs Investor's Business Daily
03:05PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN) PR Newswire
01:43PM  [$$] Alexion's Shakeup Continues as Four Executives Exit The Wall Street Journal
01:17PM  What To Make Of the Alexion Shake-up Investopedia
01:11PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Pharmaceuticals, Inc. - ALXN PR Newswire
12:42PM  Alexions top management shake-up includes CFO who started in December MarketWatch
12:24PM  BMO: Too Early to Tell If Alexion's Management Shakeup Bodes Well for Stock TheStreet.com
12:18PM  Here's Why Alexion Pharma (ALXN) Stock is Sinking Today Zacks
12:01PM  Alexion stock plummets 9% after top management shake-up MarketWatch
11:53AM  Alexion: Look Out Below! Barrons.com
09:29AM  Biotech Movers: Cerus, Alexion, NantKwest TheStreet.com
08:00AM  Alexion Announces Executive Leadership Changes Business Wire
May-21-17 05:08PM  Stocks That Fell to 3-Year Lows in the Week of May 19 GuruFocus.com
May-19-17 04:30PM  Amgen, Gilead, Biogen Won't Lead The Biotech Boom So Who Will? Investor's Business Daily
01:09PM  5 Reasons Big Biotech Could Gain 25%-30% Barrons.com
12:02PM  Why Stay Bullish On Gilead Barrons.com
May-18-17 07:00PM  For millions of Chinese with rare diseases, some relief in sight Reuters
06:51PM  Cramer's lightning round: It's OK to own this stock as long as you're diversified CNBC
10:30AM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Alexion Pharmaceuticals, Inc. Investors Business Wire
May-17-17 05:55PM  Alexion's (ALXN) Strensiq Results Positive in Long-Term Study Zacks
12:03PM  Here's Why Omeros Corporation Is Surging Again Today Motley Fool
May-16-17 12:01PM  Moderna Can't Escape My Intellectual Property, Says Arbutus CEO Forbes
08:04AM  3 Top Healthcare Stocks to Buy Now Motley Fool
06:30AM  Rady Childrens Institute for Genomic Medicine and Alexion Pharmaceuticals Partner to Speed the Diagnosis of Rare Genetic Disorders in Newborns Business Wire
May-15-17 08:00AM  Long-term Data Confirm Benefits of Treatment with Strensiq® (asfotase alfa) in Adolescents and Adults with Hypophosphatasia (HPP) Through Five Years Business Wire
May-11-17 09:07AM  ALXN1210 Is Expected to Boost Alexion Pharmaceuticals Revenue Market Realist
08:59AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : May 11, 2017 Capital Cube
07:36AM  Alexion Pharmaceuticals Has Raised Its 2017 Earnings Guidance Market Realist
06:30AM  Alexion Global Headquarters Earns Highest LEED® Green Building Certification Business Wire
May-10-17 02:35PM  New Patient Starts Expected to Drive Soliriss Revenue in 2017 Market Realist
01:05PM  Alexion Pharmaceuticals Projects Robust 2017 Revenue Performance Market Realist
11:09AM  Analysts Latest Recommendations for Alexion and Its Peers Market Realist
May-09-17 10:00AM  Alexion to Present at the Bank of America Merrill Lynch 2017 Health Care Conference Business Wire
09:12AM  Alexion Shares Under Pressure Amid Brazilian Office Raid; Barclays Says Buy The Dip Benzinga
May-08-17 02:57PM  BioMarin: Is Profitability On The Horizon? Barrons.com
12:00PM  Brazilian Police Raid Alexion Offices in Sales Probe TheStreet.com
10:56AM  Alexion Raided by Brazilian Police in Sales Practices Probe Bloomberg
May-05-17 09:30AM  Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene Zacks
May-04-17 05:59PM  5 Healthcare Innovators I'm Still Buying Zacks
May-01-17 10:41AM  Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 1, 2017 Capital Cube
Apr-28-17 09:10PM  Edited Transcript of ALXN earnings conference call or presentation 27-Apr-17 2:00pm GMT Thomson Reuters StreetEvents
08:22AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US : April 28, 2017 Capital Cube
Apr-27-17 09:48PM  Alexion Rises More Than 5% After Beating Consensus TheStreet.com +5.12%
05:45PM  Alexion Beats On First-Quarter Sales; Profits Top By 15 Cents Investor's Business Daily
04:48PM  AbbVie Flirts With Buy Point After Q1 Earnings, Sales Top Investor's Business Daily
04:43PM  Celgene Dips On $95 Million Lag In Psoriasis Sales, But Earnings Top Investor's Business Daily
03:51PM  Three Biotechs EnterOne Biotech Gains Barrons.com
02:42PM  Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View Zacks
02:31PM  Alexion (ALXN) Tops Q1 Earnings, Sales; Shares Up Zacks
09:27AM  Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes TheStreet.com
06:52AM  Alexion beats Street 1Q forecasts Associated Press
06:30AM  Alexion Reports First Quarter 2017 Results Business Wire
Apr-24-17 12:33PM  Is This Why Akari Therapetuics PLC Is Falling Today? Motley Fool
Apr-21-17 04:13PM  Street Watches To See If $125,000 Drug Boosts Biogen's Results Investor's Business Daily
09:19AM  Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise? Zacks
Apr-20-17 05:53PM  What to expect from biotech CNBC Videos
Apr-19-17 11:42AM  Gilead Sciences: Who's Frustrated Now? Barrons.com
09:21AM  3 Beaten-Up Healthcare Stocks: Are They Bargains? Motley Fool
Apr-18-17 06:00AM  The 7 Most Expensive Prescription Drugs in the World Motley Fool
Apr-16-17 02:02PM  3 Big Reasons to Be Bullish on Biotech Stocks Motley Fool
Apr-13-17 04:18PM  The Hot Stock: Alexion Pharmaceuticals Climbs 3.3% Barrons.com
Apr-12-17 11:25AM  [$$] Celgene, Biogen to Gain From Higher Prices Barrons.com
Apr-06-17 10:00AM  Alexion to Report First Quarter 2017 Results on Thursday, April 27, 2017 Business Wire
Apr-04-17 03:15PM  Alexion Pharmaceuticals Slid 9.9% in March -- but Why? Motley Fool
11:05AM  [$$] Beaten-Down Biotechs May Be Worth Buying Barrons.com
Apr-03-17 12:12PM  3 Top Growth Stocks Priced at a Bargain This Spring Motley Fool
Mar-31-17 10:27AM  Akari Gets Fast Track Status for Coversin Drug Investopedia
Mar-30-17 04:08PM  Which Biotechs Are Buyable As Sector Recovers In 2017? Investor's Business Daily
09:23AM  Coverage initiated on Alexion Pharma by UBS
Mar-29-17 08:15AM  Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study Investopedia
Mar-28-17 05:03PM  Here's Why Omeros Corporation Stock Climbed Higher Today Motley Fool
Mar-27-17 05:29PM  [$$] Alexion Names New CEO Following Internal Sales-Practice Probe The Wall Street Journal
10:50AM  Alexion Pharma names former Baxalta chief Ludwig Hantson CEO Reuters
08:24AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
08:07AM  Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO
06:43AM  Alexion Pharma names former Baxalta head Ludwig Hantson CEO
06:30AM  Alexion Appoints Ludwig Hantson, Ph.D., as Chief Executive Officer Business Wire
Mar-24-17 09:02AM  Omeros: Power in the Pipeline at Motley Fool
Mar-23-17 10:16AM  Alexion (ALXN) Files for Soliris' Label Expansion in Japan
09:36AM  Biotech Premarket Movers: Insys, Ultragenyx, Alexion
Mar-22-17 04:05PM  Alexion Submits Application in Japan for Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG) Business Wire
Mar-17-17 06:01PM  Alexion (ALXN) Licenses Artubus Technology for Rare Diseases
11:43AM  Alexion Buys LNP Drug Delivery Tech from Arbutus at Investopedia
Mar-16-17 05:00PM  Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate GlobeNewswire
Mar-15-17 06:04AM  Pharmaceutical company to lay off more than 200 employees
Mar-14-17 12:55PM  Alexion Trims Workforce, Scraps R&D Programs at Investopedia
09:42AM  Alexion Pharmaceuticals Cuts 7% of Workforce
07:39AM  Why Did the Healthcare Sector Fall on March 13?
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Neill JulieEVP. Global OperationsMar 02Sale133.8065187,10437,864Mar 06 06:03 PM
Moriarty John BEVP & General CounselMar 01Sale132.5028237,36544,672Mar 01 07:46 PM
MACKAY MARTINEVP & Global Head of R&DMar 01Sale132.5037049,02550,688Mar 01 07:45 PM
BELL LEONARDDirectorMar 01Sale132.501,240164,300390,670Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsMar 01Sale132.5015620,67029,010Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerMar 01Sale132.5040453,53039,161Mar 01 07:44 PM
Moriarty John BEVP & General CounselFeb 28Sale131.71910119,85644,954Mar 01 07:46 PM
MACKAY MARTINEVP & Global Head of R&DFeb 28Sale131.7062582,31338,258Mar 01 07:45 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 28Sale131.7033043,46114,884Mar 01 07:45 PM
O'Neill JulieEVP. Global OperationsFeb 28Sale131.7066487,44931,015Mar 01 07:46 PM
BELL LEONARDDirectorFeb 28Sale131.712,738360,622391,910Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsFeb 28Sale131.7048063,21629,166Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerFeb 28Sale131.71915120,51533,065Mar 01 07:44 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 28Sale131.013,783495,61133,860Mar 06 06:03 PM
Moriarty John BEVP & General CounselFeb 27Sale131.2061280,29445,864Mar 01 07:46 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 27Sale131.20719,31530,197Mar 01 07:45 PM
MACKAY MARTINEVP & Global Head of R&DFeb 27Sale131.20860112,83238,883Mar 01 07:45 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 27Sale131.2026034,11215,214Mar 01 07:45 PM
O'Neill JulieEVP. Global OperationsFeb 27Sale131.20910119,39231,679Mar 01 07:46 PM
Wagner Heidi LSVP, Global Government AffairsFeb 27Sale131.2035846,97029,646Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerFeb 27Sale131.20860112,83233,980Mar 01 07:44 PM
BELL LEONARDDirectorFeb 09Sale126.8424631,203394,648Feb 10 06:05 PM
Moriarty John BEVP & General CounselFeb 09Sale126.8416721,18246,476Feb 10 06:05 PM
MACKAY MARTINEVP & Global Head of R&DFeb 09Sale126.8421727,52439,743Feb 10 06:05 PM
Carmichael ClareEVP, Chief HR OfficerFeb 09Sale126.8416721,18234,840Feb 10 06:05 PM
Moriarty John BEVP & General CounselFeb 07Sale128.0913517,29246,643Feb 08 04:40 PM
Carmichael ClareEVP, Chief HR OfficerFeb 07Sale128.0916621,26335,007Feb 08 04:40 PM
BELL LEONARDDirectorFeb 07Sale128.091,010129,371394,894Feb 08 04:40 PM
Wagner Heidi LSVP, Global Government AffairsFeb 07Sale128.0922228,43630,004Feb 08 04:38 PM
Moriarty John BEVP & General CounselFeb 06Sale125.693,403427,73946,778Feb 08 04:40 PM
O'Neill JulieEVP. Global OperationsFeb 06Sale125.692,795351,30432,589Feb 08 04:40 PM
Carmichael ClareEVP, Chief HR OfficerFeb 06Sale125.703,404427,87235,173Feb 08 04:40 PM
MACKAY MARTINEVP & Global Head of R&DFeb 06Sale125.702,728342,90439,960Feb 08 04:39 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 06Sale125.6916520,73930,268Feb 08 04:39 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 06Sale125.701,045131,35715,474Feb 08 04:39 PM
BELL LEONARDDirectorFeb 06Sale125.697,715969,728395,904Feb 08 04:40 PM
Wagner Heidi LSVP, Global Government AffairsFeb 06Sale125.691,710214,93530,226Feb 08 04:38 PM
BELL LEONARDDirectorJan 10Option Exercise22.901002,290403,719Jan 13 04:36 PM
BELL LEONARDDirectorJan 10Sale144.9910014,499403,619Jan 13 04:36 PM
BELL LEONARDDirectorJan 09Option Exercise22.904,853111,134408,472Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.9033448,397403,285Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.934,853703,345403,619Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Option Exercise54.2620,1661,094,30426,539Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Option Exercise22.9034,210783,409438,497Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.4066891,783403,619Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.5334,2104,704,730404,287Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale136.862,493341,2023,880Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale138.5420,1662,793,7526,373Jan 09 05:21 PM
Moriarty John BEVP & General CounselDec 12Sale118.611,044123,82950,181Dec 13 06:24 PM
Thiel CarstenEVP, Chief Commercial OfficerDec 09Sale130.002,308300,04030,433Dec 13 06:24 PM
Wagner Heidi LSVP, Global Government AffairsNov 14Sale115.10596,79131,936Nov 16 06:00 PM
BELL LEONARDDirectorNov 04Option Exercise22.9036,649839,262440,936Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale142.4066895,123404,287Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale140.3436,6495,143,377404,287Nov 07 07:44 PM
BELL LEONARDDirectorOct 31Option Exercise22.901,30029,770406,589Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.3733445,214404,955Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.281,300175,864405,289Nov 02 07:22 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 14Sale120.284,584551,36432,741Oct 18 06:29 PM
Wagner Heidi LSVP, Global Government AffairsOct 03Sale122.4112014,68931,995Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 03Sale122.41293,55037,325Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 13Sale129.003,000387,00037,354Sep 14 04:34 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 12Sale124.2022527,94540,354Sep 14 04:34 PM
Miller EdwardSVP, Chief Compliance OfficerSep 09Sale128.3236747,09316,519Sep 09 06:23 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 06Sale125.941,000125,94040,579Sep 08 04:33 PM
O'Neill JulieEVP. Global OperationsSep 02Sale126.2965082,08935,384Sep 02 05:11 PM
Carmichael ClareEVP, Chief HR OfficerAug 30Sale127.761,000127,76038,577Sep 01 04:57 PM
PARVEN ALVIN SDirectorAug 22Option Exercise18.0115,000270,15021,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 22Sale136.5315,0002,047,9506,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 15Sale135.5170094,8576,373Aug 24 05:33 PM
Carmichael ClareEVP, Chief HR OfficerAug 08Sale137.1416522,62839,577Aug 10 06:23 PM
Moriarty John BEVP & General CounselAug 08Sale137.1413518,51451,225Aug 10 06:23 PM
Sinha VikasEVP & CFOAug 08Sale137.1427737,988178,463Aug 10 06:23 PM
Wagner Heidi LSVP, Global Government AffairsAug 08Sale137.1422230,44532,115Aug 10 06:24 PM
BELL LEONARDDirectorAug 08Sale137.141,010138,511405,289Aug 10 06:22 PM
Hallal DavidCEOAug 08Sale137.1433245,530189,266Aug 10 06:22 PM
Moriarty John BEVP & General CounselJun 13Sale135.72918124,59151,360Jun 14 04:50 PM